---
id: 029
title: Ceftaroline (5th Generation) - MRSA Coverage
category: antimicrobials
subcategory: cephalosporins
tags: [ceftaroline, 5th-generation, MRSA, VISA, pneumonia, SSTI]
difficulty: medium
---

## Question

What makes **ceftaroline** unique among β-lactams, and what are its FDA-approved indications and dosing?

## Answer

### **Unique Feature:**
**ONLY β-lactam antibiotic with MRSA activity**

### **Mechanism of MRSA Activity:**
- Binds to **PBP2a** (altered penicillin-binding protein in MRSA) with high affinity
- Also binds PBP1, PBP2, PBP3 → cell wall synthesis inhibition

### **Spectrum:**
- **Gram-positives:** MRSA, VISA, hVISA, VRSA, MSSA, *S. pneumoniae* (including MDR)
- **Gram-negatives:** Similar to 3rd-gen cephalosporins (Enterobacterales, *H. flu*)
- **NO activity:** *Pseudomonas*, *Acinetobacter*, ESBLs, carbapenemases, anaerobes

### **FDA-Approved Indications:**

| Indication | Dose | Duration | Evidence |
|------------|------|----------|----------|
| **Acute bacterial skin/SSTI** | 600mg IV q12h | 5-14 days | Phase III: 86% cure rate |
| **Community-acquired pneumonia** | 600mg IV q12h | 5-7 days | Phase III: Non-inferior to ceftriaxone |

### **Off-Label Uses (Emerging Data):**
- MRSA bacteremia (limited data, ~74% success rate)
- Complicated MRSA infections (osteomyelitis, endocarditis)
- Salvage therapy for vancomycin-intermediate *S. aureus* (VISA)

## Key Points

### **When to Use Ceftaroline:**
- MRSA pneumonia (alternative to vancomycin)
- MRSA SSTI (complicated, IV required)
- VISA/hVISA infections (salvage therapy)
- Penicillin-resistant *S. pneumoniae* pneumonia

### **Limitations:**
- **NO *Pseudomonas* coverage** (unlike cefepime/ceftazidime)
- **Renal dosing required** (CrCl <50 mL/min → adjust to q8h at reduced dose)
- **Limited CNS penetration** (~10%) - NOT for meningitis
- **More expensive** than vancomycin or daptomycin

### **Clinical Pearls:**
- Consider for **vancomycin-intolerant** patients
- May have **faster MRSA clearance** than vancomycin (some studies)
- Not routinely recommended for bacteremia (use vancomycin or daptomycin first-line)

## Sources

- [PMC3140339: Ceftaroline for MRSA - New Cephalosporin]
- [PMC5499876: Ceftaroline for Severe MRSA Infections - Systematic Review]
- [ERJ 2024: Ceftaroline in MRSA Pneumonia Management]

## Media

N/A
